Jazz Pharmaceuticals plc – Ordinary Shares (JAZZ) reported quarterly earnings results on Tuesday, May-10-2016. The company reported $2.26 earnings per share for the quarter, missing the analyst consensus estimate by $-0.06. Analysts had a consensus of $2.32. The company posted revenue of $336.01 million in the period, compared to analysts expectations of $340.17 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.99 EPS.
Many Wall Street Analysts have commented on Jazz Pharmaceuticals plc – Ordinary Shares. Jazz Pharmaceuticals plc – Ordinary Shares was Upgraded by Sun Trust Rbsn Humphrey to ” Buy” on Apr 25, 2016. Shares were Reiterated by Mizuho on Feb 24, 2016 to “Neutral” and Lowered the Price Target to $ 124 from a previous price target of $140 .Jazz Pharmaceuticals plc – Ordinary Shares was Initiated by Wells Fargo to “Outperform” on Feb 19, 2016.
Jazz Pharmaceuticals plc – Ordinary Shares closed down -1.4 points or -0.96% at $144.35 with 7,33,442 shares getting traded on Friday. Post opening the session at $144.96, the shares hit an intraday low of $139.75 and an intraday high of $148.28 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Apr 27, 2016, Karen J Wilson (SVP, Finance & PAO) sold 604 shares at $160.00 per share price. According to the SEC, on Apr 18, 2016, Michael Patrick Miller (SVP, US Commercial) sold 100 shares at $145.79 per share price. On Apr 13, 2016, Russell J. Cox (EVP & COO) sold 4,000 shares at $136.98 per share price, according to the Form-4 filing with the securities and exchange commission.